Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Horizon Therapeutics Public Limited's Business Segments
Horizon Therapeutics Public Limited's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 944
Countrys Reported
1
Horizon Therapeutics Public Limited does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue Share by Country - FY
- United States97.8%
Revenue by Geographic Country - FY
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| United States | $ 923 | 97.8% |
Revenue by Product & Service Category - FY
- T E P E Z Z a47.2%
- K R Y S T E X X a25.9%
- R a V I C T I9.4%
- P R O C Y S B I5.6%
- Actimmune3.1%
- R a Y O S0.8%
- P E N N S a I D Two Percent0.7%
- U P L I Z N a0.2%
- B U P H E N Y L0.1%
- Q U I N S a I R0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| T E P E Z Z a | $ 446 | 47.2% |
| K R Y S T E X X a | $ 244 | 25.9% |
| R a V I C T I | $ 88 | 9.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
7 more categories available
Sign in to unlock the full Horizon Therapeutics Public Limited dataset.
Description of Horizon Therapeutics Public Limited
Horizon Therapeutics Public Limited Company is a biopharmaceutical company that focuses on researching, developing, and marketing treatments for rare and rheumatic diseases. The company was founded in 2008 and is headquartered in Dublin, Ireland, with US headquarters in Lake Forest, Illinois.
Horizon Therapeutics has a portfolio of innovative products, with a focus on orphan diseases. The company offers several products that treat rare diseases, including actimmune, which is used to treat chronic granulomatous disease and malignant osteopetrosis, and teprotumumab, a monoclonal antibody used to treat thyroid eye disease. The company also offers several rheumatology products such as KRYSTEXXA, a medication for refractory gout.
Horizon Therapeutics is committed to expanding its capabilities in the rare disease space. The company has a strong pipeline of products in various stages of development, including drugs approved by the FDA for many orphan diseases. The company is focused on the development of innovative treatments for rare diseases where there is a significant unmet need.
Horizon Therapeutics has a global presence, with operations in North America and Europe. The company has collaborations with several pharmaceutical companies to expand its portfolio and develop new drugs. They have agreements with HemoShear Therapeutics, Inc., and River Vision Development Corporation.
Horizon Therapeutics has a strong financial position, with total revenue of $2.4 billion in 2019. The company is committed to creating value for its shareholders, and it has grown exponentially over the years.
In conclusion, Horizon Therapeutics is a biopharmaceutical company committed to improving the lives of people living with rare and rheumatic diseases. With a strong pipeline and collaborations with other pharmaceutical companies, Horizon Therapeutics is well-positioned for continued growth and success into the future.
Horizon Therapeutics has a portfolio of innovative products, with a focus on orphan diseases. The company offers several products that treat rare diseases, including actimmune, which is used to treat chronic granulomatous disease and malignant osteopetrosis, and teprotumumab, a monoclonal antibody used to treat thyroid eye disease. The company also offers several rheumatology products such as KRYSTEXXA, a medication for refractory gout.
Horizon Therapeutics is committed to expanding its capabilities in the rare disease space. The company has a strong pipeline of products in various stages of development, including drugs approved by the FDA for many orphan diseases. The company is focused on the development of innovative treatments for rare diseases where there is a significant unmet need.
Horizon Therapeutics has a global presence, with operations in North America and Europe. The company has collaborations with several pharmaceutical companies to expand its portfolio and develop new drugs. They have agreements with HemoShear Therapeutics, Inc., and River Vision Development Corporation.
Horizon Therapeutics has a strong financial position, with total revenue of $2.4 billion in 2019. The company is committed to creating value for its shareholders, and it has grown exponentially over the years.
In conclusion, Horizon Therapeutics is a biopharmaceutical company committed to improving the lives of people living with rare and rheumatic diseases. With a strong pipeline and collaborations with other pharmaceutical companies, Horizon Therapeutics is well-positioned for continued growth and success into the future.
Horizon Therapeutics Public Limited Company is a biopharmaceutical company that is deeply committed to the development and commercialization of innovative therapies aimed at addressing unmet medical needs, particularly in the realms of rare diseases and rheumatic conditions. The company has established a comprehensive portfolio of products, a diverse pipeline of therapeutics, and a robust infrastructure to support patients in need of specialized care.
Segments
1. Rare Diseases:
Horizon Therapeutics has prioritized its efforts on rare diseases that are often serious and underdiagnosed. The focus in this segment includes:
- Krabbe Disease: A rare genetic disorder affecting the nervous system.
- Farber Disease: A type of lysosomal storage disorder characterized by joint pain, swelling, and recurrent respiratory issues.
- Niemann-Pick Disease: This encompasses type A and B forms of this genetic disorder which affects lipid metabolism and can lead to severe neurological issues.
- Lysosomal Acid Lipase Deficiency: A rare and serious genetic condition leading to the accumulation of fats in the liver and organs, affecting metabolism.
2. Rheumatology:
This segment concentrates on treatments that address chronic inflammatory conditions that greatly impact the quality of life of patients. The prime focus areas include:
- Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting joints, causing pain, swelling, and potential joint damage.
- Gout: A type of arthritis characterized by sudden instabilities in joint inflammation due to high uric acid levels.
3. Inflammation:
The inflammation segment targets innovative therapies to manage conditions characterized by chronic inflammation, including:
- Behçets Syndrome: A rare condition that causes blood vessel inflammation and can lead to various systemic complications.
- Castleman’s Disease: A group of disorders involving an overgrowth of lymph nodes and related tissues.
- Idiopathic Pulmonary Fibrosis (IPF): A serious lung disease characterized by progressive scarring of lung tissue, leading to respiratory problems.
Products
Horizon Therapeutics has developed several flagship therapies that are FDA-approved and widely recognized:
1. Krystexxa:
An injectable medication designed to treat chronic gout in adults who have not responded to conventional therapies. It is an innovative therapy that helps to lower uric acid levels in the body, thus preventing gout attacks.
2. Tepezza:
Recognized as the first-in-class treatment for active thyroid eye disease. Tepezza addresses the inflammation and discomfort patients experience due to this rare autoimmune condition affecting the eyes.
3. Procysbi:
An oral medication aimed at the long-term management of nephropathic cystinosis, a rare metabolic disorder that leads to kidney damage. It is approved for patients aged one year and older.
4. Rayos:
This delayed-release formulation is versatile in treating various inflammatory conditions such as rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, and ankylosing spondylitis, providing patients with dose flexibility and symptom control.
Services
In addition to its product offerings, Horizon Therapeutics also provides essential services tailored to support patients and healthcare providers:
1. Pharmacy Services:
Horizon’s pharmacy services focus on facilitating access to medications through cost-reduction strategies and ensuring patients receive the medications they require without delay, regardless of their financial circumstances.
2. Patient Access Programs:
These programs are designed to assist uninsured and underinsured patients in obtaining Horizon medications either for free or at a significantly reduced cost, thereby improving overall access to treatment.
3. Clinical Trials:
Horizon actively conducts clinical trials to assess the safety and efficacy of both new and existing therapeutic products. Collaborations with academic institutions, research organizations, and other pharmaceutical innovators are pivotal in advancing treatment options for patients with rare and rheumatic illnesses.
Conclusion
Horizon Therapeutics Public Limited Company stands out in the biopharmaceutical landscape with its dedicated approach to addressing rare diseases, rheumatologic conditions, and inflammatory diseases. Through a multifaceted portfolio of FDA-approved products and a comprehensive array of support services, Horizon is committed to improving the lives of patients facing significant health challenges while continually investing in research and development to foster innovation in the industry.
Segments
1. Rare Diseases:
Horizon Therapeutics has prioritized its efforts on rare diseases that are often serious and underdiagnosed. The focus in this segment includes:
- Krabbe Disease: A rare genetic disorder affecting the nervous system.
- Farber Disease: A type of lysosomal storage disorder characterized by joint pain, swelling, and recurrent respiratory issues.
- Niemann-Pick Disease: This encompasses type A and B forms of this genetic disorder which affects lipid metabolism and can lead to severe neurological issues.
- Lysosomal Acid Lipase Deficiency: A rare and serious genetic condition leading to the accumulation of fats in the liver and organs, affecting metabolism.
2. Rheumatology:
This segment concentrates on treatments that address chronic inflammatory conditions that greatly impact the quality of life of patients. The prime focus areas include:
- Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting joints, causing pain, swelling, and potential joint damage.
- Gout: A type of arthritis characterized by sudden instabilities in joint inflammation due to high uric acid levels.
3. Inflammation:
The inflammation segment targets innovative therapies to manage conditions characterized by chronic inflammation, including:
- Behçets Syndrome: A rare condition that causes blood vessel inflammation and can lead to various systemic complications.
- Castleman’s Disease: A group of disorders involving an overgrowth of lymph nodes and related tissues.
- Idiopathic Pulmonary Fibrosis (IPF): A serious lung disease characterized by progressive scarring of lung tissue, leading to respiratory problems.
Products
Horizon Therapeutics has developed several flagship therapies that are FDA-approved and widely recognized:
1. Krystexxa:
An injectable medication designed to treat chronic gout in adults who have not responded to conventional therapies. It is an innovative therapy that helps to lower uric acid levels in the body, thus preventing gout attacks.
2. Tepezza:
Recognized as the first-in-class treatment for active thyroid eye disease. Tepezza addresses the inflammation and discomfort patients experience due to this rare autoimmune condition affecting the eyes.
3. Procysbi:
An oral medication aimed at the long-term management of nephropathic cystinosis, a rare metabolic disorder that leads to kidney damage. It is approved for patients aged one year and older.
4. Rayos:
This delayed-release formulation is versatile in treating various inflammatory conditions such as rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, and ankylosing spondylitis, providing patients with dose flexibility and symptom control.
Services
In addition to its product offerings, Horizon Therapeutics also provides essential services tailored to support patients and healthcare providers:
1. Pharmacy Services:
Horizon’s pharmacy services focus on facilitating access to medications through cost-reduction strategies and ensuring patients receive the medications they require without delay, regardless of their financial circumstances.
2. Patient Access Programs:
These programs are designed to assist uninsured and underinsured patients in obtaining Horizon medications either for free or at a significantly reduced cost, thereby improving overall access to treatment.
3. Clinical Trials:
Horizon actively conducts clinical trials to assess the safety and efficacy of both new and existing therapeutic products. Collaborations with academic institutions, research organizations, and other pharmaceutical innovators are pivotal in advancing treatment options for patients with rare and rheumatic illnesses.
Conclusion
Horizon Therapeutics Public Limited Company stands out in the biopharmaceutical landscape with its dedicated approach to addressing rare diseases, rheumatologic conditions, and inflammatory diseases. Through a multifaceted portfolio of FDA-approved products and a comprehensive array of support services, Horizon is committed to improving the lives of patients facing significant health challenges while continually investing in research and development to foster innovation in the industry.